Effects of Donepezil and Memantine on Cognitive Functions After a Sleep Deprivation Challenge in Healthy Volunteers

NCT ID: NCT01461174

Last Updated: 2015-02-04

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 36 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2011-11-30
• Study Completion Date: 2014-11-30

Brief Summary

The aim of this study is to assess the utility of sleep deprivation as a potential model for prediction of clinical efficacy using a combination of cognitive physiological endpoints.

Detailed Description

BACKGROUND:

With the inherent difficulty of detecting significant improvements in cognitive performance in normal healthy subjects, it is presently incredibly hard to predict and select efficacious agents early in the drug development process. As such the potential success of novel therapeutic agents for the symptomatic relief of Alzheimer's disease (AD) is largely unknown until the drugs enter relatively large studies, assessing clinical outcome over at least a six month period. To try to overcome this issue, clinical scientists have focused their attention to the development of cognitive endpoints/biomarkers that can be detected in a number of experimental paradigms where cognitive impairments akin to those observed in AD, have been artificially induced.Based on the scientific literature, the use of total Sleep Deprivation in healthy volunteers seems to be a good paradigm to assess potential anti-AD agents.

It is the first multicenter study that combines 3 complementary approaches via a standardization of the sleep deprivation model: cognitive evaluations, imaging and neurophysiology.

STUDY OBJECTIVE(S)

Primary:

The study aim is to assess the utility of sleep deprivation as a potential model for prediction of clinical efficacy using a combination of cognitive physiological endpoints.

The main goals are to test the effects of donepezil and memantine treatment on cognitive functions in young healthy deprived subjects and to assess the potential restoring effect of the two drugs on cognitive functions induce by sleep deprivation.

Secondary:

• To assess that Sleep Deprivation model results in cognitive impairments
• To determine the sensitivity of the model by testing the restoring effects of one single dose of modafinil
• To investigate the reversal effect of modafinil on EEG under sleep deprivation.
• To investigate the reversal effect of modafinil on fMRI acquisitions under sleep deprivation (subjects that will be included in Toulouse will not have fMRI)
• To investigate the influence of donepezil and memantine on EEG under sleep deprivation.
• To investigate the influence of donepezil and memantine on fMRI acquisitions under sleep deprivation (subjects that will be included in Toulouse will not have fMRI).

STUDY DESIGN The study is a phase I, multicentric (Lille, Marseille, Toulouse), randomised, placebo-controlled, cross-over design.

STUDY POPULATION Healthy young male subjects from 25 to 40 years-old (36 subjects randomized)

PRIMARY ENDPOINT(S) AND MAIN SECONDARY ENDPOINT(S)

Primary endpoint:

N-back test

Secondary endpoints:

• Other cognitive assessments
• Imaging
• Neurophysiology

Conditions

Healthy

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: CROSSOVER
• Blinding Strategy: QUADRUPLE

Study Groups

Modafinil

200 mg tablet, single dose

Group Type: EXPERIMENTAL

Modafinil

Intervention Type: DRUG

200 mg tablet, single dose

Donepezil

5 mg tablet one per day, 15 days

Group Type: EXPERIMENTAL

Donepezil

Intervention Type: DRUG

Donepezil or placebo, 5 mg tablet one per day, 15 days

Memantine

10 mg tablet one per day, 15 days

Group Type: EXPERIMENTAL

Memantine

Intervention Type: DRUG

Memantine or placebo, 10 mg tablet one per day, 15 days

Interventions

Modafinil

200 mg tablet, single dose

Intervention Type: DRUG

Donepezil

Donepezil or placebo, 5 mg tablet one per day, 15 days

Intervention Type: DRUG

Memantine

Memantine or placebo, 10 mg tablet one per day, 15 days

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

Demography

1. Healthy male subjects aged between 25 and 40 years-old inclusive

2. BMI between 18 kg/m2 to 27 kg/m2

Health status

3. The subjects is in good health on the basis of the medical interview (medical history, symptoms) and the physical examination, vital signs and the results of blood chemistry and hematology.

4. ECG (12 leads) normal (120 < PR < 200 ms; QRS < 120ms; QTcF < 450ms) and/or without clinically relevant impairments as judged by investigator.

5. The subject does not smoke or smokes a maximum of 5 cigarettes per day and is able to stop during the days of the study.

6. No claustrophobia (fMRI)

7. The subject has normal visual and auditory abilities

Specific to the study

8. Habitual good sleeping: sleeping on average 6,5 to 9 hours each night in the past month assessed by the Pittsburgh Quality Index.

9. Regular sleeping hours whereby they sleep no later than 1 am and rise before 9 am in the past month assessed by the Pittsburgh Quality Index.

10. The subject can complete the neuropsychological test battery during the training session

11. The subject corresponds to an extravert personality according to the Eysenck Personality Inventory

12. The subject is right-handed (Edinburgh Handedness Inventory, Imaging measurement condition).

Regulations

13. The subjects is able to read and understand the Information Form and comply with the protocol instructions and restrictions

14. Subjects are covered by a social insurance

15. Subjects have provided written informed consent

Exclusion Criteria

Medical history and clinical status

1. History or presence of psychiatric illness assessed by a psychiatric interview with the Mini-International Neuropsychiatric Interview (M.I.N.I-DSM IV).

2. History or presence of neurologic illness or others illnesses (general medical interview)

3. The subject has caffeine intake of greater than 5 drinks per day or excessive energy drink type intake.

4. The subject has an orthostatic blood pressure reduction > 20 mm Hg, based on a difference of systolic blood pressure between supine and after standing for 3 minutes.

General conditions

5. The patient, in the opinion of the investigator, is unlikely to comply with the study protocol or is unsuitable for any other reason

6. The subject participates to another clinical trial or is still being within a washout period of a previous clinical trial, or subjects who received more than 4500 euros in the previous 12 months.

Specific to the study

7. History or presence of daytime sleepiness with the Epworth scale (score > 10, pathological sleepiness).

8. History of obstructive sleep apnea assessed by the Berlin questionnaire.

9. History of periodic leg movements assessed by Restless Legs Syndrome questionnaire.

10. Extreme chronotypes: score at the Horne Ostberg scale (< 31 or > 69).

11. Jet lag > 2 hours in the last two weeks.

12. No time-shifted work during the last month.

• Minimum Eligible Age: 25 Years
• Maximum Eligible Age: 40 Years
• Eligible Sex: MALE
• Accepts Healthy Volunteers: Yes

Sponsors

European Union

OTHER

Sponsor Role: collaborator

Qualissima

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Christine Audebert

Role: PRINCIPAL_INVESTIGATOR

CIC CPCET

Locations

CIC

Lille, , France

MEDES

Toulouse, , France

Countries

France

Other Identifiers

2011-000344-25

Identifier Type: EUDRACT_NUMBER

Identifier Source: secondary_id

WP1P001

Identifier Type: -

Identifier Source: org_study_id